(GWO) Great-West Lifeco - Ratings and Ratios

Great-West Lifeco Inc. is a diversified financial services company operating in Canada, the United States, and Europe, offering a range of life and health insurance, retirement savings, wealth, and asset management products. The companys extensive product portfolio includes life insurance, disability, and critical illness coverage, as well as retirement savings plans, annuity products, and wealth management services. With a presence in multiple markets, Great-West Lifeco distributes its products through various channels, including its sales force, brokers, consultants, and financial institutions, under brand names such as Canada Life, Irish Life, and Empower.

From a business perspective, Great-West Lifecos diverse revenue streams and geographic presence provide a solid foundation for stability and growth. The companys asset management services cater to institutional clients, including pension schemes, insurance companies, and sovereign wealth funds, further expanding its reach. With a history dating back to 1891, Great-West Lifeco has established itself as a reputable player in the financial services industry.

Analyzing the , we observe that the stocks current price is $51.98, slightly above its 20-day simple moving average (SMA) of $51.13, indicating a potential upward trend. The 50-day SMA at $52.20 is nearby, which could act as a resistance level. The stocks average true range (ATR) is $0.98, or 1.89%, suggesting relatively moderate volatility. Considering the , the companys market capitalization stands at approximately $48.36 billion CAD, with a price-to-earnings (P/E) ratio of 12.64 and a forward P/E of 11.15, indicating a relatively stable valuation. The return on equity (RoE) is 13.93%, suggesting a decent level of profitability.

Based on the and , a forecast for Great-West Lifeco Inc. could be as follows: Given the stocks current price and the nearby resistance level at $52.20, a potential short-term target could be around $53.50, assuming the stock can break through the 50-day SMA. However, if the stock fails to gain momentum, it may retreat to the 20-day SMA at $51.13. In the longer term, the companys stable valuation, decent profitability, and diversified revenue streams could support a gradual increase in stock price, potentially reaching $60.00 within the next 12-18 months, assuming favorable market conditions and continued operational performance.